BOSTON, Oct. 20 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company has increased its sales revenue for the third quarter of 2008. Solos Endoscopy sales revenue grew by more than $17,000 to $114,186, compared to $96,530 for the same period of 2007. This report represents the second time in two years that sales for the third quarter have increased, up 18% from 2007 and up 37% from $83,251 in 2006.
"We are very excited about increasing our market share and the number of units sold while maintaining consistent unit pricing over the last two and a half years. These numbers reflect Solos Endoscopy's business development efforts; we are on track to meet the goals set down in our business plan," stated Bob Segersten, President of Solos Endoscopy, Inc.
Solos Endoscopy generates its revenues through the sale of its extensive line of medical products, which include imaging systems, hand held surgical instruments and endoscopic equipment. The Company's unaudited third quarter financial statements will soon be made available on the Pink Sheets at www.pinksheets.com.
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos' sales team can help make the right buying decisions for the hospital, surgery center, or physician office. Additional information is available on the Company's website at: www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
CONTACT: Investor Relations for Solos Endoscopy, Inc., +1-866-THE-APPL(E),
+1-866-843-2775
Web site: http://www.pinksheets.com/
http://www.solosendoscopy.com/
